keyword
MENU ▼
Read by QxMD icon Read
search

heart failure update

keyword
https://www.readbyqxmd.com/read/28929822/genetic-and-ethnic-modulation-of-cardiovascular-toxicity-of-vascular-endothelial-growth-factor-inhibitors
#1
Yen-Chou Chen, Cheng-Chih Chung, Yung-Kuo Lin, Yi-Jen Chen
Vascular endothelial growth factor (VEGF) inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs), are important as anticancer treatments through curbing tumor angiogenesis and growth. VEGF inhibitors have significant cardiovascular effects. By blocking VEGF receptors, ligands, or signal pathways, VEGF inhibitors disturb the balance between vasodilation and vasoconstriction, undermine endothelial cell integrity, and activate cardiomyocyte apoptosis. VEGF inhibitors increase risks of hypertension, heart failure, thromboembolism, and arrhythmia...
September 20, 2017: Annals of Medicine
https://www.readbyqxmd.com/read/28920861/pharmacotherapy-of-type-2-diabetes-an-update
#2
REVIEW
Jagriti Upadhyay, Stergios A Polyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula A Paschou, Niki Katsiki, Patricia Underwood, Kyung-Hee Park, Jochen Seufert, Eun Seok Kang, Elliot Sternthal, Asterios Karagiannis, Christos S Mantzoros
Type 2 diabetes (T2DM) is a leading cause of morbidity and mortality worldwide and a major economic burden. The prevalence of T2DM is rising, suggesting more effective prevention and treatment strategies are necessary. The aim of this narrative review is to summarize the pharmacologic treatment options available for patients with T2DM. Each therapeutic class is presented in detail, outlining medication effects, side effects, glycemic control, effect on weight, indications and contraindications, and use in selected populations (heart failure, renal insufficiency, obesity and the elderly)...
September 8, 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/28882290/the-potential-of-clinical-phenotyping-of-heart%C3%A2-failure-with-imaging-biomarkers-for%C3%A2-guiding%C3%A2-therapies-a-focused-update
#3
REVIEW
Partho P Sengupta, Christopher M Kramer, Jagat Narula, Vasken Dilsizian
The need for noninvasive assessment of cardiac volumes and ejection fraction (EF) ushered in the use of cardiac imaging techniques in heart failure (HF) trials that investigated the roles of pharmacological and device-based therapies. However, in contrast to HF with reduced EF (HFrEF), modern HF pharmacotherapy has not improved outcomes in HF with preserved EF (HFpEF), largely attributed to patient heterogeneity and incomplete understanding of pathophysiological insights underlying the clinical presentations of HFpEF...
September 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28877448/gene-therapy-for-heart-failure-status-quo-and-quo-vadis
#4
Olympia Bikou, Kiyotake Ishikawa
Gene therapy is recently attracting increased attention and cardiac gene therapy is not an exception. Advances in gene transfer vectors, development of new vector delivery methods, and discovery of new gene targets continue to fuel our motivation to use this approach in routine bedside care. In the past two years, we have witnessed important advances in the field, as the results of three recently completed cardiac gene therapy programs have been published. Unfortunately, none of the trials have met their primary efficacy endpoints, but sub-analysis demonstrated potential efficacy...
June 2017: Discovery Medicine
https://www.readbyqxmd.com/read/28872494/the-genetics-of-congenital-heart-disease%C3%A2-understanding-and-improving-long-term-outcomes-in-congenital-heart-disease-a-review-for-the-general-cardiologist-and-primary-care-physician
#5
M Abigail Simmons, Martina Brueckner
PURPOSE OF REVIEW: This review has two purposes: to provide an updated review of the genetic causes of congenital heart disease (CHD) and the clinical implications of these genetic mutations, and to provide a clinical algorithm for clinicians considering a genetics evaluation of a CHD patient. RECENT FINDINGS: A large portion of congenital heart disease is thought to have a significant genetic contribution, and at this time a genetic cause can be identified in approximately 35% of patients...
October 2017: Current Opinion in Pediatrics
https://www.readbyqxmd.com/read/28858984/effects-of-blood-pressure-lowering-treatment-on-outcome-incidence-12-effects-in-individuals-with-high-normal-and-normal-blood-pressure-overview-and-meta-analyses-of-randomized-trials
#6
Costas Thomopoulos, Gianfranco Parati, Alberto Zanchetti
BACKGROUND: It is currently unknown whether individuals with SBP/DBP values in the ranges 120-139/80-89 mmHg, usually defined as with prehypertension or high-normal and normal blood pressure (BP), benefit from BP-lowering treatment and whether benefits in these individuals depend on the level of their cardiovascular risk. OBJECTIVES: Meta-analyzing all available data from randomized controlled trials (RCTs) about the effects on cardiovascular outcomes of BP-lowering treatment in individuals with normal or high-normal BP values in absence of baseline antihypertensive drugs and free from a recent myocardial infarction, left ventricular dysfunction and heart failure...
August 30, 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/28856732/predictive-model-and-risk-factors-associated-with-a-revised-definition-of-early-allograft-dysfunction-in-liver-transplant-recipients
#7
R Nicolau-Raducu, A J Cohen, A Bokhari, H Bohorquez, D Bruce, I Carmody, E Bugeaud, J Seal, D Sonnier, B Nossaman, G Loss
INTRODUCTION: Early allograft dysfunction (EAD) is a well-defined clinical syndrome that reflects overall graft function within the first week after transplant. The aim of this study was to further refine the definition for EAD. METHOD: In this study, 1124 patients were included for analysis. Logistic regression was performed to identify markers of liver injury associated with 6-month patient and graft failure. RESULTS: Recursive partitioning identified cut-points for ALT/AST >3000/6000IU/dL observed within 1(st) week, with bilirubin ≥10mg/dL and INR ≥1...
August 30, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28853057/erratum-to-updates-in-cardiac-resynchronization-therapy-for-chronic-heart-failure-review-of-multisite-pacing
#8
Antonios P Antoniadis, Ben Sieniewicz, Justin Gould, Bradley Porter, Jessica Webb, Simon Claridge, Jonathan M Behar, Christopher Aldo Rinaldi
No abstract text is available yet for this article.
October 2017: Current Heart Failure Reports
https://www.readbyqxmd.com/read/28852999/sex-and-cardiovascular-involvement-in-inflammatory-joint-diseases
#9
REVIEW
Santos Castañeda, Carlos González-Juanatey, Miguel A González-Gay
The term inflammatory joint disease (IJD) encompasses a group of chronic conditions with predominant joint involvement. They share an increased risk of cardiovascular (CV) complications. However, the implication of the sex in the risk of CV disease in IJD has not been specifically addressed. The aim of this work is to assess the influence of sex on the clinical expression of CV manifestations associated to IJD. With this objective, an update of the current knowledge of the sex influence on CV disease in patients with IJD was conducted...
August 29, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28834396/rehospitalization-after-intermittent-levosimendan-treatment-in-advanced-heart-failure-patients-a-meta-analysis-of-randomized-trials
#10
Simona Silvetti, Alessandro Belletti, Antonella Fontana, Piero Pollesello
AIMS: Intermittent levosimendan administration has been suggested to improve survival in patients with advanced heart failure (AdHF). Quality of life is a key issue for AdHF patients and is negatively affected by frequent hospitalizations. METHODS AND RESULTS: CENTRAL, Google Scholar, MEDLINE/PubMed, Scopus, and the Cochrane Central Register of clinical trials (updated 15/1/2017) were searched for randomized controlled trials investigating the effect of intermittent levosimendan administration in patients with AdHF...
June 29, 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/28810678/update-on-heart-failure-biomarkers-intensive-therapy-remote-monitoring-and-cardiomyocyte-renewal
#11
Thomas F Lüscher
No abstract text is available yet for this article.
August 7, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28803840/development-and-validation-of-risk-equations-for-complications-of-type-2-diabetes-recode-using-individual-participant-data-from-randomised-trials
#12
Sanjay Basu, Jeremy B Sussman, Seth A Berkowitz, Rodney A Hayward, John S Yudkin
BACKGROUND: In view of substantial mis-estimation of risks of diabetes complications using existing equations, we sought to develop updated Risk Equations for Complications Of type 2 Diabetes (RECODe). METHODS: To develop and validate these risk equations, we used data from the Action to Control Cardiovascular Risk in Diabetes study (ACCORD, n=9635; 2001-09) and validated the equations for microvascular events using data from the Diabetes Prevention Program Outcomes Study (DPPOS, n=1018; 1996-2001), and for cardiovascular events using data from the Action for Health in Diabetes (Look AHEAD, n=4760; 2001-12)...
August 10, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28800093/omega-3-fatty-acids-and-cardiovascular-disease-summary-of-the-2016-agency-of-healthcare-research-and-quality-evidence-review
#13
REVIEW
Ethan M Balk, Alice H Lichtenstein
We summarize the 2016 update of the 2004 Agency of Healthcare Research and Quality's evidence review of omega-3 fatty acids and cardiovascular disease (CVD). The overall findings for the effects of marine oil supplements on intermediate CVD outcomes remain largely unchanged. There is high strength of evidence, based on numerous trials, of no significant effects of marine oils on systolic or diastolic blood pressures, but there are small, yet statistically significant increases in high density lipoprotein and low density lipoprotein cholesterol concentrations...
August 11, 2017: Nutrients
https://www.readbyqxmd.com/read/28781147/durable-mechanical-circulatory-support-in-teenagers-and-adults-with-congenital-heart-disease-a-systematic-review
#14
Jill M Steiner, Eric V Krieger, Karen K Stout, April Stempien-Otero, Claudius Mahr, Nahush A Mokadam, Joshua L Hermsen
BACKGROUND: Heart failure is the leading cause of morbidity and mortality for adults with congenital heart disease (ACHD). Many patients are ineligible for transplantation, and those who are eligible often face long wait times with high wait-list morbidity. Durable mechanical circulatory support (MCS) may be an option for many patients. This systematic review evaluates the published literature on the use of durable MCS in teenagers and adults with congenital heart disease. METHODS: A comprehensive search of MEDLINE (PubMed), EMBASE, and the Cochrane Library was performed electronically in July 2015 and updated in March 2016, guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines...
August 2, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28780660/update-on-valvular-heart-disease-in-pregnancy
#15
REVIEW
Lucy M Safi, Sarah V Tsiaras
Valvular heart disease in women of childbearing age poses an increased risk of adverse maternal and fetal outcomes, and management in pregnancy can be challenging. Ideally, patients with suspected valvular disease should have preconception counseling by a multidisciplinary team including cardiologists with expertise in pregnancy and a maternal-fetal medicine specialist. Preconception planning should include a cardiac assessment of maternal risk, determination of frequency of surveillance, and a cardiovascular management plan during delivery...
September 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28777254/t-type-and-l-type-calcium-channel-blockers-for-the-treatment-of-cardiac-iron-overload-an-update
#16
Sirinart Kumfu, Siriporn C Chattipakorn, Nipon Chattipakorn
In thalassemia patients iron overload cardiomyopathy is a major cause of cardiac dysfunction and mortality. Despite many advances in the development of new iron chelating agents, heart failure still occurs in some patients and can lead to an increase in mortality rate. Recently, potential novel therapeutic strategies in the treatment of these patients have focused on L-type and T-type calcium channel blockers. These two channels have been reported as being the main routes for cardiac iron uptake under conditions of iron overload...
August 4, 2017: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/28774374/effectiveness-and-cost-effectiveness-of-serum-b-type-natriuretic-peptide-testing-and-monitoring-in-patients-with-heart-failure-in-primary-and-secondary-care-an-evidence-synthesis-cohort-study-and-cost-effectiveness-model
#17
Maria Pufulete, Rachel Maishman, Lucy Dabner, Syed Mohiuddin, William Hollingworth, Chris A Rogers, Julian Higgins, Mark Dayer, John Macleod, Sarah Purdy, Theresa McDonagh, Angus Nightingale, Rachael Williams, Barnaby C Reeves
BACKGROUND: Heart failure (HF) affects around 500,000 people in the UK. HF medications are frequently underprescribed and B-type natriuretic peptide (BNP)-guided therapy may help to optimise treatment. OBJECTIVE: To evaluate the clinical effectiveness and cost-effectiveness of BNP-guided therapy compared with symptom-guided therapy in HF patients. DESIGN: Systematic review, cohort study and cost-effectiveness model. SETTING: A literature review and usual care in the NHS...
August 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28772051/protocol-update-and-preliminary-results-of-eacvi-hfa-cardiac-oncology-toxicity-cot-registry-of-the-european-society-of-cardiology
#18
Patrizio Lancellotti, Maurizio Galderisi, Erwan Donal, Thor Edvardsen, Bogdan A Popescu, Dimitrios Farmakis, Gerasimos Filippatos, Gilbert Habib, Chiara Lestuzzi, Ciro Santoro, Marie Moonen, Guy Jerusalem, Maryna Andarala, Stefan D Anker
AIMS: European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity Registry was launched in October 2014 as a European Society of Cardiology multicentre registry of breast cancer patients referred to imaging laboratories for routine surveillance, suspected, or confirmed anticancer drug-related cardiotoxicity (ADRC). After a pilot phase (1 year recruitment and 1 year follow-up), some changes have been made to the protocol (version 1.0) and electronic case report form...
August 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/28763374/the-veterans-affairs-cardiac-risk-score-recalibrating-the-atherosclerotic-cardiovascular-disease-score-for-applied-use
#19
Jeremy B Sussman, Wyndy L Wiitala, Matthew Zawistowski, Timothy P Hofer, Douglas Bentley, Rodney A Hayward
BACKGROUND: Accurately estimating cardiovascular risk is fundamental to good decision-making in cardiovascular disease (CVD) prevention, but risk scores developed in one population often perform poorly in dissimilar populations. We sought to examine whether a large integrated health system can use their electronic health data to better predict individual patients' risk of developing CVD. METHODS: We created a cohort using all patients ages 45-80 who used Department of Veterans Affairs (VA) ambulatory care services in 2006 with no history of CVD, heart failure, or loop diuretics...
September 2017: Medical Care
https://www.readbyqxmd.com/read/28757175/-main-novelties-of-the-last-set-of-european-guidelines-for-the-management-of-heart-failure
#20
Richard Isnard, Nadjib Hammoudi, Lise Legrand, Françoise Pousset
Heart failure is the main chronic disease in cardiology. Its prognosis remains poor despite improvements in its management that allow patients to live increasingly longer with this disease, alternating periods of stability and episodes of decompensation. Treatment guidelines are regularly updated to integrate new results of recent trials that are likely to influence routine care. These guidelines are proposed with different classes of recommendations and difference levels of evidence. It is of paramount importance to summarize the guidelines to make them accessible to the vast majority of cardiologists and easier to read to promote their application...
July 2017: La Presse Médicale
keyword
keyword
110951
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"